These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 945238)

  • 21. Abnormalities of chemotactic lymphokine synthesis and mononuclear leukocyte chemotaxis in Wiskott-Aldrich syndrome.
    Altman LC; Snyderman R; Blaese RM
    J Clin Invest; 1974 Aug; 54(2):486-93. PubMed ID: 4136226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of cell mediated immunity in leprosy.
    Dubey GK; Joglekar VK; Hardas UD; Chaubey BS
    Lepr India; 1981 Apr; 53(2):197-203. PubMed ID: 7253571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced complement-mediated immune complex solubilization in leprosy patients.
    Ramanathan VD; Sharma P; Ramu G; Sengupta U
    Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological status of maculoanaesthetic leprosy: leucocyte migration inhibition test as a measure of cell mediated immune response.
    Rao SS; Rao PR
    Lepr India; 1981 Jul; 53(3):340-9. PubMed ID: 7278138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous responses to irritants and microbial antigens in lepromatous leprosy.
    Meneghini CL; Angelini G; Lospalluti M; Trimigliozzi G
    Trans St Johns Hosp Dermatol Soc; 1974; 60(1):91-3. PubMed ID: 4466014
    [No Abstract]   [Full Text] [Related]  

  • 26. Leprosy XII. Quantitative analysis of thymus-derived lymphocyte response to phytohemagglutinin in leprosy.
    Lim SD; Jacobson RR; Park BH; Good RA
    Int J Lepr Other Mycobact Dis; 1975; 43(2):95-100. PubMed ID: 1081499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients.
    Converse PJ; Mshana RM; Bjune GJ
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):548-53. PubMed ID: 3655466
    [No Abstract]   [Full Text] [Related]  

  • 28. The relationship of the P-K titre to the serum IgE level in patients with leprosy.
    Hamburger RN; Fernandez-cruz E; Arnaiz A; Perez B; Bootello A
    Clin Exp Immunol; 1974 Jun; 17(2):253-60. PubMed ID: 4143279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 1 reactions in leprosy--heterogeneity in T-cell functions related to the background leprosy type.
    Laal S; Mishra RS; Nath I
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):481-93. PubMed ID: 2958570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients.
    Lamas-Robles C; González-Mendoza A; Pérez-Suárez G; Mejía-Arreguín S
    Int J Lepr Other Mycobact Dis; 1985 Sep; 53(3):373-7. PubMed ID: 3876399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Kveim test in leprosy.
    Krishnamurthy S; Verghese R; Job CK
    Int J Lepr Other Mycobact Dis; 1975; 43(4):333-8. PubMed ID: 1241690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro studies on the effect of levamisole in lepromatous leprosy.
    Birdi TJ; Mistry NF; Mahadevan PR; Antia NH
    J Clin Lab Immunol; 1984 Feb; 13(2):93-6. PubMed ID: 6374154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class specific anti-Mycobacterium leprae antibody assay in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment.
    Melsom R; Harboe M; Naafs B
    Int J Lepr Other Mycobact Dis; 1982 Sep; 50(3):271-81. PubMed ID: 6754639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaria, leprosy and dapsone.
    Saha K; Kapoor L; Arora VM; Chattopadhya D
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):501-4. PubMed ID: 15115119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative DNCB epicutaneous sensitization in leprosy patients and controls.
    Sivamani S; Garg BR; Lal S
    Lepr India; 1981 Jan; 53(1):45-51. PubMed ID: 7218763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions.
    Shen JY; Hofman FM; Gunter JR; Modlin RL; Rea TH
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):494-8. PubMed ID: 2443587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phytohaemagglutinin (PHA)-induced transformation of peripheral blood-lymphocytes in leprosy patients.
    Ghei SK; Sengupta U; Ramu G
    Lepr India; 1980 Apr; 52(2):223-8. PubMed ID: 6969819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunologic aspects of leprosy].
    Ayed K
    Acta Leprol; 1989; 7(1):37-40. PubMed ID: 2696319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined clofazimine- and dapsone-resistant leprosy. A case report.
    Kar HK; Bhatia VN; Harikrishnan S
    Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of expression of intercellular adhesion molecule ICAM-1 in lepromatous leprosy patients.
    Moncada B; Torres-Alvarez MB; Gonzalez-Amaro R; Fuentes-Ahumada C; Baranda L; Delgado SP; Garcia R
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):581-5. PubMed ID: 7512116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.